X
All Data
Lead Product(s): Olopatadine Hydrochloride
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
Dr. Reddy’s has launched of over-the-counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the storebrand equivalents of Pataday® Once Daily Relief and Pataday® Twice Daily Relief, in the U.S. market, as approved by the USFDA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cetirizine
Therapeutic Area: Ophthalmology Product Name: Zerviate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Nicox SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 05, 2021
Details:
Nicox will receive an undisclosed license fee and potential milestone payments linked to regulatory approval and sales, and is eligible to receive double digit royalties on net sales of ZERVIATE.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Alvotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 02, 2021
Details:
As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
